We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma.
- Authors
Melichar, B; Koralewski, P; Ravaud, A; Pluzanska, A; Bracarda, S; Szczylik, C; Chevreau, C; Filipek, M; Delva, R; Sevin, E; Négrier, S; McKendrick, J; Santoro, A; Pisa, P; Escudier, B
- Abstract
In patients with untreated metastatic renal cell carcinoma (mRCC), progression-free survival (PFS) was longer with bevacizumab + interferon (IFN)-alpha than IFN + placebo (AVOREN trial). In this hypothesis-generating study, subgroup analysis was carried out to determine the effect of IFN dose reduction.
- Publication
Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Vol 19, Issue 8, p1470
- ISSN
1569-8041
- Publication type
Journal Article
- DOI
10.1093/annonc/mdn161